Table 4.
Disease progression and evolution by MDS subtype according to FAB and WHO classification, and by IPSS and WPSS prognostic category
| FAB classification | Patients evolved | Percent |
|---|---|---|
| RA | 39/282 | 13.8 |
| RARS | 20/76 | 26.3 |
| RAEB | 136/257 | 52.9 |
| RAEB-T | 27/33 | 81.8 |
| CMML | 48/114 | 42.1 |
| Unclassified | 5/16 | 31.3 |
| Total | 275/778 | 35.3 |
| Unknown | 77 | |
| WHO classification | ||
| RA | 13/158 | 8.2 |
| Del (5q) | 3/16 | 18.8 |
| RCMD | 23/110 | 20.9 |
| RARS | 5/49 | 10.2 |
| RCMD-RS | 15/22 | 68.2 |
| RAEB-1 | 70/150 | 46.7 |
| RAEB-2 | 65/106 | 61.3 |
| CMML-D | 19/50 | 38.0 |
| CMML-P | 29/64 | 45.3 |
| MDS/MPD | 8/16 | 50.0 |
| Unclassified | 1/6 | 16.7 |
| IPSS (N = 575) | ||
| Low | 38/228 | 16.7 |
| Int-1 | 76/189 | 40.2 |
| Int-2 | 65/103 | 63.1 |
| High | 33/55 | 60.0 |
| WPSS (Ν = 444) | ||
| Very low | 11/131 | 8.4 |
| Low | 18/81 | 22.2 |
| Intermediate | 33/77 | 42.9 |
| High | 69/114 | 60.5 |
| Very high | 18/41 | 43.9 |